Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by National Pension Service

National Pension Service raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 186,310 shares of the biopharmaceutical company’s stock after acquiring an additional 3,887 shares during the quarter. National Pension Service owned approximately 0.17% of Regeneron Pharmaceuticals worth $163,634,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in REGN. Everpar Advisors LLC purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $782,000. Charles Schwab Investment Management Inc. raised its holdings in Regeneron Pharmaceuticals by 3.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 620,616 shares of the biopharmaceutical company’s stock valued at $545,081,000 after acquiring an additional 22,558 shares during the last quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management lifted its stake in shares of Regeneron Pharmaceuticals by 13.3% during the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 1,667 shares of the biopharmaceutical company’s stock worth $1,464,000 after purchasing an additional 196 shares during the period. Apollon Wealth Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 32.3% during the fourth quarter. Apollon Wealth Management LLC now owns 1,287 shares of the biopharmaceutical company’s stock worth $1,130,000 after purchasing an additional 314 shares during the last quarter. Finally, Lincoln National Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 49.7% during the fourth quarter. Lincoln National Corp now owns 771 shares of the biopharmaceutical company’s stock worth $677,000 after purchasing an additional 256 shares during the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total transaction of $98,205.00. Following the completion of the transaction, the director now owns 18,282 shares in the company, valued at approximately $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $982.05, for a total value of $98,205.00. Following the sale, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 854 shares of the company’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $979.25, for a total transaction of $836,279.50. Following the completion of the transaction, the director now owns 1,382 shares of the company’s stock, valued at approximately $1,353,323.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 8,095 shares of company stock valued at $7,779,766. 8.83% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have commented on REGN shares. BMO Capital Markets lifted their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. UBS Group raised their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. Sanford C. Bernstein assumed coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 price objective for the company. Morgan Stanley raised their target price on shares of Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a research note on Wednesday, March 13th. Finally, Bank of America upped their price target on shares of Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research report on Friday, April 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $981.71.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded down $14.21 during trading hours on Wednesday, reaching $955.76. The company’s stock had a trading volume of 390,075 shares, compared to its average volume of 495,489. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The company’s 50 day simple moving average is $942.67 and its 200 day simple moving average is $899.44. Regeneron Pharmaceuticals, Inc. has a one year low of $684.80 and a one year high of $998.33. The stock has a market cap of $104.91 billion, a P/E ratio of 28.24, a price-to-earnings-growth ratio of 2.74 and a beta of 0.17.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.